1. Published

   The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

   Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.

   Research output: Contribution to conference › Paper

2. Published

   Economic evaluation of on-demand maintenance therapy with proton pump inhibitors in patients with symptomatic gastroesophageal reflux disease - a Monte-Carlo analysis for Italy

   Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Oct 2004.

   Research output: Contribution to conference › Paper

3. Published

   All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

   Research output: Book/Report › Commissioned report

4. Published

   The British antibiotic and silver-impregnated catheters for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial): study protocol

   Hughes, D., Jenkinson, M. D., Gamble, C., Hartley, J. C., Hickey, H., Hughes, D. A., Blundell, M., Griffiths, M. J., Solomon, T. & Malluci, C. L., 3 Jan 2014, In: Trials. 15, 14

   Research output: Contribution to journal › Article › peer-review

5. Published

   Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

   Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Feb 2006, Unknown.

   Research output: Book/Report › Commissioned report

6. Published

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Sept 2003.

   Research output: Contribution to conference › Paper

7. Published

   Use of PK-PD modelling to predict the impact of non-compliance

   Hughes, D. & Hughes, D. A., 1 Nov 2003.

   Research output: Contribution to conference › Paper

8. Published

   Multiple imputation of multiple multi-item scales when a full imputation model is infeasible

   Hughes, D., Plumpton, C. O., Morris, T., Hughes, D. A. & White, I. R., 26 Jan 2016, In: BMC Research Notes. 9, 45, p. 1-15

   Research output: Contribution to journal › Article › peer-review

9. Published

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D. & Hughes, D. A., 1 Jun 2003.

   Research output: Contribution to conference › Paper

10. Published

    Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Aug 2007, In: Clinical Pharmacology and Therapeutics. 82, 2, p. 123-127

    Research output: Contribution to journal › Article › peer-review

11. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

12. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Mar 2008

    Research output: Non-textual form › Web publication/site

13. Published

    Sources of resilience and their moderating relationships with harms from adverse childhood experiences. Report 1: Mental illness

    Hughes, K., Ford, K., Davies, A., Homolova, L. & Bellis, M., 18 Jan 2018, Public Health Wales NHS Trust. 60 p.

    Research output: Book/Report › Other report › peer-review

14. Published

    Economics of pharmacogenetic guided treatments: Underwhelming or overstated?

    Hughes, D., May 2018, In: Clinical Pharmacology and Therapeutics. 103, 5, p. 749-751

    Research output: Contribution to journal › Article › peer-review

15. Published

    Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group

    Hughes, D., Linck, P. G., Hiligsmann, M., Salas, M., Hughes, D. A., Manias, E., Gwadry-Sridhar, F. H., Linck, P. & Cowell, W., 1 Dec 2013, In: Osteoporosis International. 24, 12, p. 2907-2918

    Research output: Contribution to journal › Article › peer-review

16. Published

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Jul 2005.

    Research output: Contribution to conference › Paper

17. Published

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Nov 2005, In: QJM - An International Journal of Medicine. 98, 11, p. 829-836

    Research output: Contribution to journal › Article › peer-review

18. Published

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Jan 2009.

    Research output: Contribution to conference › Paper

19. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109

    Research output: Contribution to journal › Article › peer-review

20. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

21. Published

    The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors

    Hughes, D., Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A. L., Deloukas, P., Daly, A. K., Aarons, L., Ogungbenro, K., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Jan 2012, In: British Journal of Clinical Pharmacology. 73, 1, p. 66-76

    Research output: Contribution to journal › Article › peer-review

22. Published

    Decision-Makers’ Preferences for Approving New Medicines in Wales: A Discrete-Choice Experiment with Assessment of External Validity

    Hughes, D., Linley, W. G. & Hughes, D. A., 1 Apr 2013, In: Pharmacoeconomics. 31, 4, p. 345-355

    Research output: Contribution to journal › Article › peer-review

23. Published

    Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios

    Hughes, D., Parham, P. E. & Hughes, D. A., 16 Feb 2015, In: Philosophical Transactions B: Biological Sciences. 370, 1665

    Research output: Contribution to journal › Article › peer-review

24. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003, In: Value in Health. 6, 6, p. 749

    Research output: Contribution to journal › Article › peer-review

25. Published

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Jan 2004, In: Drug Safety. 27, 8, p. 535-554

    Research output: Contribution to journal › Article › peer-review

26. Published

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Jan 2004, In: Pharmacoeconomics. 22, 16, p. 1047-1059

    Research output: Contribution to journal › Article › peer-review

27. Published

    Pharmacogenetic tests: the need for a level playing field

    Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Jan 2013, In: Nature Reviews Drug Discovery. 12, 3-4

    Research output: Contribution to journal › Article › peer-review

28. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

29. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

30. Published

    Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population

    Hughes, D., Mulhern, B., Rowen, D., Snape, D., Jacoby, A., Marson, T., Hughes, D. A., Baker, G. & Brazier, J., 1 Jul 2014, In: Epilepsy and Behavior. 36, p. 12-17

    Research output: Contribution to journal › Article › peer-review

31. Published

    Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

    Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

32. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

33. Published

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Oct 2007.

    Research output: Contribution to conference › Paper

34. Published

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Jun 2006.

    Research output: Contribution to conference › Paper

35. Published

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

36. Published

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

37. Published

    Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

    Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Dec 2012, In: Value in Health. 15, 8, p. 1162-1171

    Research output: Contribution to journal › Article › peer-review

38. Published

    Rationing of drugs for rare diseases

    Hughes, D. & Hughes, D. A., 1 Apr 2006.

    Research output: Contribution to conference › Paper

39. Published

    Less is more: Medicines that require less frequent administration improve adherence, but are they better?

    Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 3, p. 211-213

    Research output: Contribution to journal › Article › peer-review

40. Published

    Rationing of drugs for rare diseases.

    Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 4, p. 315-316

    Research output: Contribution to journal › Article › peer-review

41. Published

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

42. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

43. Published

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Jan 2009, p. TP40.

    Research output: Contribution to conference › Paper

44. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

45. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

46. Published

    Orphan drugs revisited: author's response.

    Hughes, D. & Hughes, D. A., 1 May 2006, In: Quarterly Journal of Medicine. 99, 5, p. 350-351

    Research output: Contribution to journal › Article › peer-review

47. Published

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Mar 2010, In: Clinical Pharmacology and Therapeutics. 87, 3, p. 257-261

    Research output: Contribution to journal › Article › peer-review

48. Published

    Understanding medication compliance and persistence from an economics perspective

    Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Jan 2008, In: Value in Health. 11, 4, p. 600-610

    Research output: Contribution to journal › Article › peer-review

49. Published

    Welsh Health Economics Network (WHEN): Scoping Report.

    Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Jan 2005, 2005 ed. Unknown.

    Research output: Book/Report › Commissioned report

50. Published

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report